Reps. Trone, Meuser Introduce EFFECTIVE Act to Grant the FDA More Authority to Clamp Down on Ineffective Opioids Entering Drug Market
July 29, 2022
July 29, 2022
WASHINGTON, July 29 -- Rep. David Trone, D-Maryland, issued the following news release:
Congressmen David Trone (D-MD) and Dan Meuser (R-PA) introduced the Ensuring the FDA Fully Examines Clinical Trial Impact and Vitalness before Endorsement (EFFECTIVE) Act to allow the FDA to deny a new drug application for an opioid if it is not clinically superior to other commercially available drugs.
This effort would provide further authority to the FDA to review the potential pu . . .
Congressmen David Trone (D-MD) and Dan Meuser (R-PA) introduced the Ensuring the FDA Fully Examines Clinical Trial Impact and Vitalness before Endorsement (EFFECTIVE) Act to allow the FDA to deny a new drug application for an opioid if it is not clinically superior to other commercially available drugs.
This effort would provide further authority to the FDA to review the potential pu . . .